Venner Shipley, an intellectual property (IP) law firm with focuses including life sciences, pharmaceuticals and medtech, has ...

AAX Biotech, a biotechnology company specialising in antibody therapeutics, and Vascurie, a biopharmaceutical company ...

Astellas Pharma has announced that the Scottish Medicines Consortium has accepted zolbetuximab for use on the NHS in Scotland ...

Nxera Pharma has reported encouraging top-line data from a phase 3 clinical trial of its insomnia treatment daridorexant in South Korea, paving the way for a planned marketing submission in early 2026 ...

Ipsen has announced the presentation of new study data on Dysport (abobotulinumtoxinA) in stroke and other neurological ...

Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...

Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

Fabentech has received Marketing Authorisation in France for Ricimed, an antidote designed to treat ricin poisoning, marking ...

Argenx has announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

PMGroup Worldwide Ltd are pleased to announce their acquisition of the MAD World Summit and conference. This strategic ...